India, Oct. 6 -- image credit- freepik

Mumbai-based pharma major Lupin has launched Formoflo-G(R) MDI, the world's first fixed-dose triple combination metered-dose inhaler (MDI) for chronic obstructive pulmonary disease (COPD) in India, following approval from the Drug Controller General of India (DCGI).

The launch marks a significant advancement in respiratory care, expanding treatment options for patients living with COPD.

Lupin Formoflo-G(R) is a first-of-its-kind MDI that combines Glycopyrronium Bromide, Formoterol Fumarate and Fluticasone Propionate for the long-term management and treatment of moderate to severe COPD. The product is available as a twice-daily, single-strength fixed dose, bringing hope to more than 55 million peop...